Skip to content

The effects of tonsillectomy and steroid pulse therapy in patients with IgA nephropathy : multicenter,radomized trial

The effects of tonsillectomy and steroid pulse therapy in patients with IgA nephropathy : multicenter,radomized trial - tonsillectomy and steroid pulse therapy in IgA nephropathy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-C000000384
Enrollment
20
Registered
2006-03-31
Start date
2005-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA nephropathy

Interventions

combined therapy by tonsillectomy and steroid pulse therapy steroid pulse therapy alone

Sponsors

Research Group for Tonsillectomy and Steroid Pulse therapy in IgA naphropathy
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Patients with biopsy-prove IgA nephropathy 2)Relatively good prognosis group, relatively poor prognosis group and poor prognosis group 3)Urinary protein excretion is 1.0g/day or more and serum creatinine is less than 1.5mg/dl 4)Patients having chronic tonsillitis or recurrent tonsillitis 5)Systolic blood pressure is less than 140 mmHg and diastolic blood pressure is less than 90 mmHg with or without antihypertensive drugs

Exclusion criteria

Exclusion criteria: 1)Patients with nephrotic syndorome 2)Patients whose serum creatinine is 1.6mg/dl or more 3)Patients who have been treated with steroid 4)Pregnant women or women of child bearing potential and nursing women. 5)Patients who can not be given anesthetic because of cardiac failure, respiratory failure or uncontrollable severe hypertension 6)Patients in whom tonsillectomy should not be done by the decision of otorhinolaryngologists because of the difficulty of tonsillectomy or no indication 7)Patients with hypersensitivity to the drugs used in the study 8)Patients who are judged to be inappropriate for the study by the investigator or subinvestigator

Design outcomes

Secondary

MeasureTime frame
1)change in creatinine clearance from baseline, slope of 1/serum creatinine vs. time 2)incidence of events (doubling of serum creatinine or 50% decrease in creatinine clearance from baseline and dialysis) 3)percentage of adverse effects

Primary

MeasureTime frame
1)change in 24-hour urinary protein excretion and the degree of microscopic hematuria from baseline, 2)percentage of patients with clinical remission, i.e., without proteinuria and hematuria

Countries

Japan

Contacts

Public ContactYasunori Utsunomiya

The Jikei University School of Medicine Division of Kidney and Hypertension

igahenteki@jikei.ac.jp03-3433-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026